LIFE Stock Price, aTyr Pharma Inc Quote, Chart

Market Summary

USD1.57-0.03

Market Closed

-1.88%

LIFE Stock Price

View Fullscreen

LIFE RSI Chart

LIFE Valuation

Market Cap

106.4M

Price/Earnings (Trailing)

-2.11

Price/Sales (Trailing)

301.32

EV/EBITDA

-1.69

Price/Free Cashflow

-2.84

LIFE Price/Sales (Trailing)

LIFE Profitability

EBT Margin

-14276.20%

Return on Equity

-55.58%

Return on Assets

-41.76%

Free Cashflow Yield

-35.19%

LIFE Fundamentals

LIFE Revenue

Revenue (TTM)

353.0K

Rev. Growth (Qtr)

-100%

LIFE Earnings

Earnings (TTM)

-50.4M

Earnings Growth (Yr)

-96.7%

Earnings Growth (Qtr)

-30.9%

Breaking Down LIFE Revenue

Last 7 days

-1.9%

Last 30 days

-21.5%

Last 90 days

-0.6%

Trailing 12 Months

-21.1%

How does LIFE drawdown profile look like?

LIFE Financial Health

Current Ratio

6.27

Debt/Equity

0.03

Debt/Cashflow

-12.12

LIFE Investor Care

Shares Dilution (1Y)

101.87%

Diluted EPS (TTM)

-0.95

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	7.9M	5.4M	2.9M	353.0K
2022	10.4M	10.4M	10.4M	10.4M
2021	0	0	0	10.4M
2020	2.9M	5.4M	7.9M	10.5M
2019	0	0	0	422.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of aTyr Pharma Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 06, 2024	broadfoot jill marie	sold	-2,687	1.69	-1,590	chief financial officer
Feb 05, 2024	broadfoot jill marie	acquired	-	-	3,750	chief financial officer
Feb 05, 2024	shukla sanjay	acquired	-	-	10,375	president and ceo
Feb 05, 2024	denyes nancy	acquired	-	-	2,688	general counsel
Dec 12, 2023	shukla sanjay	bought	14,136	1.178	12,000	president and ceo
Dec 11, 2023	shukla sanjay	bought	3,510	1.17	3,000	president and ceo
Nov 13, 2023	shukla sanjay	bought	15,085	1.111	13,578	president and ceo
Nov 10, 2023	shukla sanjay	bought	1,618	1.138	1,422	president and ceo
Jul 28, 2023	shukla sanjay	bought	30,223	2.0149	15,000	president and ceo
May 17, 2023	coughlin timothy	gifted	-	-	-6,000	-

Which funds bought or sold LIFE recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	Bank of New York Mellon Corp	sold off	-100	-23,161	-	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	new	-	11,000	11,000	-%
Apr 23, 2024	Main Street Financial Solutions, LLC	new	-	67,226	67,226	0.01%
Apr 19, 2024	CALDWELL SUTTER CAPITAL, INC.	unchanged	-	28.00	101	-%
Apr 15, 2024	KINGSWOOD WEALTH ADVISORS, LLC	new	-	117,000	117,000	0.01%
Apr 15, 2024	PFS Partners, LLC	unchanged	-	183	663	-%
Mar 11, 2024	VANGUARD GROUP INC	added	3.72	-268,578	3,339,520	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	new	-	404,868	404,868	-%
Feb 26, 2024	Virtu Financial LLC	added	93.3	15,000	37,000	-%
Feb 16, 2024	GSA CAPITAL PARTNERS LLP	added	296	110,000	154,000	0.01%

Are Funds Buying or Selling LIFE?

Are funds buying LIFE calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own LIFE

No. of Funds

Unveiling aTyr Pharma Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	lytton laurence w	1.0%	585,013	SC 13G/A
Feb 13, 2024	stonepine capital management, llc	0.8%	482,258	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Jan 18, 2024	federated hermes, inc.	17.37%	10,169,600	SC 13G/A
Jan 02, 2024	logos global management lp	9.9%	5,800,000	SC 13G
Feb 22, 2023	lytton laurence w	8.7%	4,440,188	SC 13G
Feb 17, 2023	stonepine capital management, llc	8.9%	4,569,433	SC 13G/A
Feb 14, 2023	venrock healthcare capital partners ii, l.p.	4.0%	1,171,436	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 01, 2023	federated hermes, inc.	18.03%	5,231,600	SC 13G/A

Recent SEC filings of aTyr Pharma Inc

View All Filings

Date Filed	Form Type	Document
Apr 05, 2024	DEFA14A	DEFA14A
Apr 05, 2024	DEF 14A	DEF 14A
Apr 05, 2024	ARS	ARS
Mar 14, 2024	8-K	Current Report
Mar 14, 2024	10-K	Annual Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 13, 2024	SC 13G/A	Major Ownership Report
Feb 09, 2024	SC 13G/A	Major Ownership Report
Feb 06, 2024	4	Insider Trading
Feb 06, 2024	4	Insider Trading

Peers (Alternatives to aTyr Pharma Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	-2.42%	-17.04%	-8.75	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.0B	1.8B	-7.18%	-26.90%	-41	9.87	76.23%	61.08%
BMRN	15.4B	2.5B	-8.70%	-12.49%	74.73	6.21	13.74%	186.89%
INCY	11.6B	3.7B	-9.54%	-29.84%	19.41	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-14.77%	-39.78%	-11.37	15.16	425.83%	18.94%
BBIO	4.4B	-	-19.35%	75.41%	-6.7	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.32%	0.89%	-14.22	12.57	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.24%	-18.54%	-44.9	3.79	40.45%	71.62%
ARWR	2.7B	240.7M	-22.93%	-36.73%	-9.23	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-8.48%	-5.52%	24.58	4.41	85.90%	-14.05%
NVAX	569.6M	983.7M	-16.08%	-46.16%	-1.05	0.58	-50.36%	17.16%
CRBP	361.2M	881.7K	-3.23%	346.43%	-8.1	466.16	-77.61%	-5.33%
INO	247.0M	4.9M	-18.88%	12.93%	-1.83	50.76	-54.97%	51.71%
IBIO	6.1M	2.1M	-47.62%	62.96%	-0.22	2.14	-13.45%	66.37%

aTyr Pharma Inc News

Latest updates

aTyr Pharma Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2
Revenue	-100.0%	-	353,000	-	-	-	-	-	-	-	2,053,000	148,000	189,000	8,065,000	4,124,500	184,000	94,000
Operating Expenses	23.1%	15,959,000	12,968,000	13,558,000	12,787,000	18,336,000	13,492,000	12,584,000	12,378,000	8,640,000	6,993,000	6,660,000	6,507,000	6,206,000	6,106,000	5,682,000	5,735,000
S&GA Expenses	21.0%	3,204,000	2,649,000	3,718,000	3,408,000	3,426,000	3,625,000	3,449,000	3,482,000	2,685,000	2,295,000	2,044,000	2,146,000	2,590,000	2,516,000	1,883,000	2,421,000
R&D Expenses	23.6%	12,755,000	10,319,000	9,840,000	9,379,000	14,910,000	9,867,000	9,135,000	8,896,000	5,955,000	4,698,000	4,616,000	4,361,000	3,616,000	3,590,000	3,799,000	3,314,000
EBITDA Margin	-1086.5%	-140	-11.85	-6.35	-4.34	-3.30	-3.29	-3.28	-3.27	-3.26	-3.21	-	-	-	-	-	-
Interest Expenses	0%	39,000	39,000	48,000	46,000	54,000	-	-	-	-	-	-	-	-	-	-	-
EBT Margin	-1083.5%	-142	-12.06	-6.43	-4.38	-3.32	-3.32	-3.31	-3.31	-3.31	-3.30	-	-	-	-	-	-
Net Income	-30.9%	-14,792,000	-11,300,000	-12,342,000	-11,952,000	-7,520,000	-13,244,000	-12,421,000	-12,154,000	-8,556,500	-4,931,000	-6,599,000	-6,447,000	1,752,000	-5,973,000	-5,645,000	-5,848,000
Net Income Margin	-847.3%	-142	-15.07	-8.39	-5.73	-4.37	-4.46	-3.92	-3.72	-3.23	-1.55	-	-	-	-	-	-
Free Cashflow	-9.5%	-11,079,000	-10,116,000	-14,405,000	-1,836,000	-11,488,000	-12,707,000	-9,170,000	-10,162,000	-8,104,000	-5,406,000	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-3.5%	121	125	133	137	96.00	96.00	96.00	105	116	124	49.00	55.00	39.00	42.00	48.00	54.00	36.00	44.00	49.00	50.00	53.00
Current Assets	-4.0%	103	107	114	119	81.00	85.00	93.00	103	114	122	46.00	52.00	36.00	38.00	44.00	50.00	32.00	39.00	44.00	45.00	51.00
Cash Equivalents	130.3%	23.00	10.00	12.00	21.00	10.00	18.00	8.00	8.00	2.00	60.00	2.00	13.00	17.00	18.00	22.00	39.00	9.00	17.00	15.00	13.00	23.00
Net PPE	-2.0%	6.00	6.00	6.00	5.00	3.00	1.00	1.00	0.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	2.00	2.00	2.00
Current Liabilities	27.4%	16.00	13.00	12.00	14.00	14.00	11.00	9.00	6.00	6.00	6.00	7.00	4.00	6.00	8.00	10.00	10.00	13.00	12.00	11.00	11.00	11.00
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3.00	5.00	6.00	8.00
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3.00	5.00	7.00	9.00	8.00	8.00	8.00	8.00
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3.00	5.00	6.00	8.00
Shareholder's Equity	-7.9%	91.00	98.00	106	110	71.00	77.00	86.00	98.00	109	117	41.00	50.00	31.00	32.00	36.00	42.00	21.00	27.00	30.00	29.00	34.00
Retained Earnings	-3.3%	-468	-453	-441	-429	-417	-410	-396	-384	-372	-363	-356	-345	-338	-333	-327	-320	-322	-316	-310	-304	-298
Additional Paid-In Capital	1.2%	559	552	548	540	490	488	484	484	482	481	397	395	370	366	363	363	344	343	341	334	332
Shares Outstanding	8.1%	63.00	59.00	57.00	53.00	29.00	29.00	28.00	28.00	19.00	18.00	15.00	14.00	-	-	-	-	-	-	-	-	-
Minority Interest	-0.5%	-0.19	-0.19	-0.18	-0.18	-0.18	-0.18	-0.18	-0.18	-0.17	-0.17	-0.17	-0.17	-0.17	-0.16	-0.16	-0.16	-0.16	-	-	-	-
Float	-	-	-	121	-	-	-	77.00	-	-	-	76.00	-	-	-	25.00	-	-	-	10.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-15.7%	-11,062	-9,559	-12,010	-590	-10,369	-12,281	-9,117	-10,119	-8,086	-11,470	-7,692	-5,827	-5,401	-5,555	-6,403	2,058	-4,916	-4,253	-4,821	-6,023	-4,839
Share Based Compensation	-0.8%	659	664	658	619	605	615	517	417	414	442	398	360	340	324	378	423	425	278	509	571	602
Cashflow From Investing	306.5%	17,818	4,383	-4,156	-38,172	1,999	20,649	9,971	14,626	-49,348	-14,849	-3,974	-23,395	3,203	1,740	-9,449	11,406	-1,220	7,209	2,291	-3,355	-2,133
Cashflow From Financing	125.0%	6,034	2,682	8,018	49,496	918	3,013	39.00	1,481	28.00	83,869	1,271	24,857	999	334	-1,969	16,779	-1,995	-122	4,072	-619	-1,613

LIFE Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenues:
Total revenues	$ 353	$ 10,386	$ 0
Revenue, Product and Service [Extensible Enumeration]	License and collaboration agreement revenues	License and collaboration agreement revenues	License and collaboration agreement revenues
Operating expenses:
Research and development	$ 42,293	$ 42,808	$ 23,264
General and administrative	12,979	13,982	10,751
Total operating expenses	55,272	56,790	34,015
Loss from operations	(54,919)	(46,404)	(34,015)
Total other income (expense), net	4,522	1,061	238
Consolidated net loss	(50,397)	(45,343)	(33,777)
Net loss attributable to noncontrolling interest in Pangu BioPharma Limited	8	5	9
Net loss attributable to aTyr Pharma, Inc.	$ (50,389)	$ (45,338)	$ (33,768)
Net loss per share - basic	$ (0.94)	$ (1.6)	$ (1.77)
Net loss per share - diluted	$ (0.94)	$ (1.6)	$ (1.77)
Shares used in computing net loss per share, basic	53,606,488	28,419,569	19,080,878
Shares used in computing net loss per share, diluted	53,606,488	28,419,569	19,080,878

LIFE Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 22,544	$ 9,981
Available-for-sale investments	75,622	56,165
Other receivables	2,436	11,775
Prepaid expenses	2,390	2,950
Total current assets	102,992	80,871
Restricted cash	3,484	3,165
Property and equipment, net	5,531	3,059
Operating lease, right-of-use assets	6,727	7,250
Financing lease, right-of-use assets	1,788	1,248
Other assets	131	193
Total assets	120,653	95,786
Current liabilities:
Accounts payable	3,529	3,106
Accrued expenses	11,559	9,862
Current portion of operating lease liability	831	630
Current portion of financing lease liability	497	264
Total current liabilities	16,416	13,862
Long-term operating lease liability, net of current portion	12,339	9,633
Long-term financing lease liability, net of current portion	1,428	1,007
Commitments and contingencies (Note 6)
Stockholders’ equity:
Preferred stock, $0.001 par value per share; 5,000,000 undesignated authorized shares as of December 31, 2023 and 2022, respectively; no shares issued or outstanding as of December 31, 2023 and 2022, respectively
Common stock, $0.001 par value per share; 170,000,000 and 85,000,000 authorized shares as of December 31, 2023 and 2022, respectively; issued and outstanding shares - 63,286,404 and 29,498,488 as of December 31, 2023 and 2022, respectively	63	29
Additional paid-in capital	558,692	489,502
Accumulated other comprehensive loss	(74)	(433)
Accumulated deficit	(468,023)	(417,634)
Total aTyr Pharma stockholders’ equity	90,658	71,464
Noncontrolling interest in Pangu BioPharma Limited	(188)	(180)
Total stockholders' equity	90,470	71,284
Total liabilities and stockholders’ equity	$ 120,653	$ 95,786

About aTyr Pharma Inc

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of solid tumors. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.

CEO	Dr. Sanjay S. Shukla M.D., M.S.
WEBSITE	atyrpharma.com
INDUSTRY	Biotechnology
EMPLOYEES	65

aTyr Pharma Inc Frequently Asked Questions

What is the ticker symbol for aTyr Pharma Inc? What does LIFE stand for in stocks?

LIFE is the stock ticker symbol of aTyr Pharma Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of aTyr Pharma Inc (LIFE)?

As of Fri Apr 26 2024, market cap of aTyr Pharma Inc is 106.37 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LIFE stock?

You can check LIFE's fair value in chart for subscribers.

What is the fair value of LIFE stock?

You can check LIFE's fair value in chart for subscribers. The fair value of aTyr Pharma Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of aTyr Pharma Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for LIFE so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is aTyr Pharma Inc a good stock to buy?

The fair value guage provides a quick view whether LIFE is over valued or under valued. Whether aTyr Pharma Inc is cheap or expensive depends on the assumptions which impact aTyr Pharma Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LIFE.

What is aTyr Pharma Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, LIFE's PE ratio (Price to Earnings) is -2.11 and Price to Sales (PS) ratio is 301.32. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LIFE PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on aTyr Pharma Inc's stock?

In the past 10 years, aTyr Pharma Inc has provided -0.473 (multiply by 100 for percentage) rate of return.